GHRP-6
Fat LossGhrelin-receptor agonist / researchExperimental
Hexapeptide GH secretagogue that also strongly stimulates appetite via GHSR. Not FDA-approved. WADA S2 (GHRPs).
For research use only.
Key Facts
- CAS
- 87616-84-0
- Molecular Weight (MW)
- 873.0 g/mol
- Half-life
- ~30 minutes
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- 2–3× daily
- Last updated
- 8/23/2026
- Targets
- GHSR (ghrelin receptor)
Overview
Hexapeptide GH secretagogue that also strongly stimulates appetite via GHSR. Not FDA-approved. WADA S2 (GHRPs).
Protocol
- Dosage Range
- 100–200 mcg per injection
- Frequency
- 2–3× daily
- Cycle
- 8–12 weeks on / 4 weeks off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Add 2 mL bacteriostatic water per 5 mg vial.
Science
Mechanism of Action
GHSR agonist that increases GH, and typically hunger, gastric motility, and to some extent cortisol/prolactin.
Targets
GHSR (ghrelin receptor)
Studies
- GHRP-6 GH secretagogue— Journal/year not available
Benefits
GH-axis and appetite research
Potential Side Effects
- Marked hunger
- Water retention
- Cortisol increase
References
- PMID 7688450External link · Year —
- WADA Prohibited List 2026External link · Year —